CD274 and lung adenocarcinoma: MRX34 is a therapeutic liposome that was used to deliver miR-34a mimics into a syngeneic mouse lung adenocarcinoma model, promoting the recruitment of TILs and reducing the population of CD8+ PD-1+ exhausted T cells in vivo via the p53/miR-34/PD-L1 axis [270].